While immune checkpoint inhibition (ICI) shows limited efficacy in ovarian cancer (OC), we aimed to understand tumor/immune features defining ICI response in OC to identify biomarkers of treatment success.
We analyzed archival tumor and pre- and 6 weeks post-treatment blood from NRG-GY003, a phase II trial of Nivolumab ± Ipilimumab in OC. We compared Clinical Benefit (CB: complete/partial response, stable disease >24 weeks) and No Clinical Benefit (NCB: progressive disease, stable disease